DSIP in the treatment of withdrawal syndromes from alcohol and opiates.

Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R

European neurology1 Jan 1984Cited by 21 (Europe PMC)

PMID6548969DOI10.1159/000115715PepBankPUB-06548969

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In inpatients with opiate withdrawal, clinical symptoms disappeared or improved markedly in 97% after intravenous DSIP.
In plain wordsIn people with opiate withdrawal, symptoms went away or improved markedly in 97% after DSIP, without a comparison group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseClinical symptoms of opiate withdrawal
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (human).
Measurements
Symptoms disappeared or improved markedly
97%
opiate withdrawal
Source sentences
Summary
In, respectively, 97 and 87% of opiate and alcohol addicts, the clinical symptoms and signs disappeared after DSIP administration or improved markedly and rapidly.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal.
Summary · context
The assessment of effect was based on the clinical evaluation by the physician and the nursing staff.
Report a problemFND-0654896901
02HumanNon-randomized trialEfficacy outcome
In inpatients with alcohol withdrawal, clinical symptoms disappeared or improved markedly in 87% after intravenous DSIP.
In plain wordsIn people with alcohol withdrawal, symptoms went away or improved markedly in 87% after DSIP, without a comparison group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseClinical symptoms of alcohol withdrawal
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (human).
Measurements
Symptoms disappeared or improved markedly
87%
alcohol withdrawal
Source sentences
Summary
In, respectively, 97 and 87% of opiate and alcohol addicts, the clinical symptoms and signs disappeared after DSIP administration or improved markedly and rapidly.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal.
Summary · context
The assessment of effect was based on the clinical evaluation by the physician and the nursing staff.
Report a problemFND-0654896902
03HumanNon-randomized trialEfficacy outcome
In inpatients with alcohol or opiate withdrawal, anxiety decreased more slowly than the other symptoms after DSIP.
In plain wordsIn people in withdrawal, anxiety eased more slowly than other symptoms after DSIP.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseAnxiety during withdrawal
Study
n: not reported in source
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Anxiety, however, was slower to decrease.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal.
Summary · context
The assessment of effect was based on the clinical evaluation by the physician and the nursing staff.
Report a problemFND-0654896903
04HumanNon-randomized trialEfficacy outcome
On average, opiate withdrawal had a longer clinical course and needed more DSIP injections than alcohol withdrawal.
In plain wordsPeople in opiate withdrawal needed longer treatment and more DSIP injections than people in alcohol withdrawal.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
Not applicableCourse and number of DSIP injections, opiate versus alcohol withdrawal
Study
n: not reported in source
Comparator
Alcohol withdrawal patients
Outcome group
Addiction, withdrawal and alcohol intake · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
On the average, the clinical symptomatology had a more prolonged course and a higher number of DSIP injections were required for opiate addicts than for alcoholics.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal.
Summary · context
The assessment of effect was based on the clinical evaluation by the physician and the nursing staff.
Report a problemFND-0654896904
05HumanNon-randomized trialSafety outcome
Tolerance to DSIP treatment was good, apart from headaches reported by a few patients.
In plain wordsDSIP was well tolerated in people in withdrawal, apart from headaches in a few patients.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
Not applicableTolerability and headache
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Tolerance to the DSIP treatment was good, aside from headaches reported by a few patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, DSIP was administered intravenously to 107 inpatients presenting with symptoms of alcohol (n = 47) or opiate (n = 60) withdrawal.
Summary · context
The assessment of effect was based on the clinical evaluation by the physician and the nursing staff.
Report a problemFND-0654896905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.